Director George M. Milne Jr. Receives Stock Options in Amylyx Pharmaceuticals

This Form 4 filing reports that George M. Milne Jr., a director of Amylyx Pharmaceuticals, Inc., received 24,372 stock options on June 4, 2026. The options have an exercise price of $14.31 per share and expire on June 3, 2036. The options will vest in full on the earlier of June 4, 2027 or the date of the next annual meeting, subject to Milne's continued service with the company. The transaction represents an award of derivative securities (stock options) rather than a purchase or sale of common stock. As a director, Milne is required to report this equity compensation award to the SEC. The filing was signed by Joshua B. Cohen as attorney-in-fact on June 8, 2026.